Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PLRX | US
0
0%
Healthcare
Biotechnology
30/06/2024
08/06/2026
1.15
1.14
1.16
1.13
Pliant Therapeutics Inc. a clinical stage biopharmaceutical company discovers develops and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474 a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095 a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics Inc. was incorporated in 2015 and is based in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.7%1 month
35.6%3 months
44.2%6 months
45.2%-
-
2.27
0.15
0.12
-2.54
1.38K
-
-205.71M
69.92M
69.92M
-
-
-
-100.00
-40.06
19.72
11.37
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.14
Range1M
0.14
Range3M
0.30
Rel. volume
0.32
Price X volume
194.78K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 5.64 | 76.67M | -0.18% | n/a | -2140.66% |
| ImmuCell Corporation | ICCC | Biotechnology | 9.7 | 75.98M | 0.94% | n/a | 67.52% |
| XBiotech Inc | XBIT | Biotechnology | 2.37 | 72.20M | 0.00% | n/a | 5.08% |
| Tenaya Therapeutics Inc. Common Stock | TNYA | Biotechnology | 0.6864 | 70.11M | -5.73% | n/a | 11.62% |
| CRDF | CRDF | Biotechnology | 1.5 | 69.82M | 0.00% | n/a | 3.52% |
| Coya Therapeutics Inc. Common Stock | COYA | Biotechnology | 4.55 | 69.26M | 2.94% | n/a | 0.00% |
| Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.27 | 68.81M | 5.55% | n/a | 0.50% |
| Heron Therapeutics Inc | HRTX | Drug Manufacturers-Specialty & Generic | 0.4536 | 68.80M | 6.13% | n/a | -471.04% |
| BeyondSpring Inc | BYSI | Biotechnology | 1.7 | 68.51M | -0.58% | n/a | -14.90% |
| Agenus Inc | AGEN | Biotechnology | 3.14 | 67.74M | -2.79% | n/a | -170.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ILAG | ILAG | Building Products & Equipment | 3.6121 | 65.23M | 3.20% | n/a | 5.48% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 6.08 | 57.88M | 3.58% | n/a | 19.98% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 8.97 | 56.17M | -0.88% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.08 | 32.10M | -0.02% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.54 | 0.53 | Cheaper |
| Ent. to Revenue | 1,376.69 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.27 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 44.22 | 72.80 | Lower Risk |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.12 | 0.25 | Cheaper |
| Market Cap | 69.92M | 3.66B | Emerging |